Sugi Holdings Co Ltd (JP:7649)
:7649
Want to see JP:7649 full AI Analyst Report?
Top Page
Sugi Holdings Co
(7649)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥3,880.00
▲(5.09% Upside)
Action:DowngradedDate:04/10/26
The score is primarily supported by strong revenue growth and improved 2026 cash generation, but is held back by thin margins and a clear step-up in debt since 2025. Technicals are mildly supportive with positive momentum, while valuation is only average due to a ~23x P/E and a modest dividend yield.
Positive Factors
Revenue Growth
Sugi’s multi-year revenue acceleration (sharp in 2025, positive in 2026) indicates durable demand and successful expansion of pharmacy and front‑end retail sales. Sustainable top-line growth supports scale, stronger purchasing power, and long-term revenue visibility tied to prescription volumes and retail reach.
Negative Factors
Thin Profitability
Net margins near 3% indicate the business is margin‑sensitive and relies on volume and reimbursement stability. Low profitability reduces the buffer against input cost inflation or pricing pressure, constrains reinvestment capacity, and makes returns vulnerable to small adverse changes in operating or policy conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sugi’s multi-year revenue acceleration (sharp in 2025, positive in 2026) indicates durable demand and successful expansion of pharmacy and front‑end retail sales. Sustainable top-line growth supports scale, stronger purchasing power, and long-term revenue visibility tied to prescription volumes and retail reach.
Read all positive factors
Sugi Holdings Co (7649) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥654.76B
Dividend Yield0.96%
Average Volume (3M)634.13K
Price to Earnings (P/E)14.4
Beta (1Y)0.17
Revenue Growth21.81%
EPS Growth67.76%
CountryJP
Employees8,724
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)51.47
Shares Outstanding189,992,510
10 Day Avg. Volume884,930
30 Day Avg. Volume634,130
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.24
Price to Sales (P/S)0.64
P/FCF Ratio10.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥3,977.50Price Target Upside7.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)188.04
Revenue Forecast (FY)¥1.08T
Sugi Holdings Co Business Overview & Revenue Model
Company Description
Sugi Holdings Co.,Ltd. operates drugstores in Japan. It also provides visiting nursing services and home care support services. As of June 1, 2019, the company operated 1,190 stores. Sugi Holdings Co.,Ltd. was founded in 1976 and is headquartered ...
How the Company Makes Money
Sugi Holdings primarily makes money through retail and pharmacy operations tied to its store network. A major revenue stream is the sale of prescription medicines via in-store dispensing pharmacies, where revenue is generated from dispensing presc...
Sugi Holdings Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
62
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Feb 2026 | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 964.38B | 1.01T | 878.02B | 744.48B | 667.65B | 625.48B |
| Gross Profit | 305.06B | 321.20B | 275.04B | 228.84B | 202.52B | 191.49B |
| EBITDA | 58.20B | 68.68B | 56.18B | 46.24B | 40.56B | 38.74B |
| Net Income | 41.25B | 44.98B | 25.69B | 21.98B | 19.01B | 19.39B |
Balance Sheet | ||||||
| Total Assets | 554.80B | 614.49B | 495.12B | 391.99B | 353.25B | 336.38B |
| Cash, Cash Equivalents and Short-Term Investments | 109.36B | 111.21B | 52.79B | 47.43B | 70.64B | 71.83B |
| Total Debt | 42.81B | 94.04B | 47.72B | 2.76B | 1.95B | 2.31B |
| Total Liabilities | 278.51B | 324.02B | 244.41B | 158.62B | 136.71B | 122.49B |
| Stockholders Equity | 276.28B | 290.46B | 250.70B | 233.36B | 216.54B | 213.89B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 63.69B | 13.31B | 8.21B | 20.09B | -13.57B |
| Operating Cash Flow | 0.00 | 86.78B | 36.94B | 39.04B | 38.28B | 7.17B |
| Investing Cash Flow | 0.00 | -69.64B | -33.28B | -30.98B | -23.26B | -23.89B |
| Financing Cash Flow | 0.00 | 41.21B | 11.63B | -5.28B | -14.21B | -5.29B |
Sugi Holdings Co Technical Analysis
Negative
3692.00
Price Trends
3523.38
Negative
3593.85
Negative
3581.30
Negative
Market Momentum
-11.10
Positive
46.32
Neutral
35.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7649, the sentiment is Negative. The current price of 3692 is above the 20-day moving average (MA) of 3516.75, above the 50-day MA of 3523.38, and above the 200-day MA of 3581.30, indicating a bearish trend. The MACD of -11.10 indicates Positive momentum. The RSI at 46.32 is Neutral, neither overbought nor oversold. The STOCH value of 35.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7649.
Sugi Holdings Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥207.67B | 12.71 | ― | 2.35% | 7.55% | 16.01% | |
69 Neutral | ¥452.49B | 14.05 | 11.37% | 3.04% | 6.32% | 8.19% | |
67 Neutral | ¥358.17B | 16.82 | ― | 0.41% | 15.81% | 27.05% | |
66 Neutral | ¥654.76B | 14.44 | 15.71% | 0.96% | 21.81% | 67.76% | |
62 Neutral | ¥922.72B | 19.41 | ― | 1.72% | ― | ― | |
60 Neutral | ¥503.87B | 16.97 | ― | 0.93% | 3.73% | 18.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7649
Sugi Holdings Co
3,453.00
530.47
18.15%
JP:9989
Sundrug Co
3,904.00
-678.69
-14.81%
JP:3391
TSURUHA Holdings
2,024.00
-203.44
-9.13%
JP:3148
Create SD Holdings Co., Ltd.
3,275.00
244.57
8.07%
JP:3349
COSMOS Pharmaceutical Corporation
6,342.00
-2,672.14
-29.64%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,813.00
497.40
15.00%
Sugi Holdings Co Corporate Events
SUGI Holdings Announces 2-for-1 Stock Split and Confirms Unchanged Effective Dividend
Apr 9, 2026
SUGI Holdings will implement a 2-for-1 stock split of its common shares, effective September 1, 2026, doubling the number of issued shares to about 380 million. The move aims to lower the share price per investment unit, making the stock more acce...
SUGI Holdings Fast-Tracks Full Control of Seki Yakuhin to Strengthen Drugstore Network
Apr 9, 2026
SUGI Holdings will accelerate its acquisition of Seki Yakuhin Co., Ltd., a drugstore and dispensing pharmacy chain rooted in Saitama Prefecture, converting it from an equity method affiliate to a consolidated subsidiary earlier than the originally...
Sugi Holdings Breaks ¥1 Trillion in Sales as Profit Surges 75%
Apr 9, 2026
Sugi Holdings reported robust consolidated results for the fiscal year ended February 28, 2026, with net sales surpassing ¥1 trillion, up 15.1% year on year, and profit attributable to owners of parent jumping 75.1%. Operating profit rose 14....
Sugi Holdings Posts Strong February Sales and Expands Store Network
Mar 13, 2026
Sugi Holdings reported solid growth for February 2026, with existing-store sales at Sugi Pharmacy rising 5.4% year on year, driven by a 2.4% increase in the drugstore segment and a strong 13.2% gain in the prescription business. On an all-store ba...
Sugi Holdings Posts Solid January Sales and Expands Store Network to 2,317
Feb 13, 2026
Sugi Holdings reported that in January 2026, Sugi Pharmacy’s existing-store sales rose 3.5%, driven by a 1.1% increase in the Drugstore Business and a robust 9.6% gain in the Prescription Business. On an all-store basis, total sales climbed ...
Sugi Holdings Posts Solid January Sales Growth and Expands Store Network
Feb 13, 2026
Sugi Holdings reported that in January 2026, existing-store sales at Sugi Pharmacy rose 3.5%, driven by a 1.1% increase in the drugstore segment and a robust 9.6% gain in the prescription business. On an all-store basis, total sales climbed 6.0%, ...
SUGI Holdings Corrects Career Details for New Auditor Candidate in Governance Notice
Jan 27, 2026
SUGI Holdings Co., Ltd. has issued a correction to its previously announced notice on management team changes, specifically revising errors in the career history of a new auditor candidate. The company clarified that the candidate assumed the role...
SUGI Holdings Revamps Executive Team to Strengthen Strategy, Governance and Growth Areas
Jan 26, 2026
SUGI Holdings Co., Ltd. has overhauled its executive managing officer structure, effective March 1, 2026, following a resolution by its board of directors on January 26, 2026. The company has expanded and clarified top management roles by appointi...
SUGI Holdings Revamps Governance Line-up Ahead of May 2026 Shareholders’ Meeting
Jan 26, 2026
SUGI Holdings has announced changes to its management structure, confirming the slate of director candidates to be submitted for approval at its 44th Ordinary General Meeting of Shareholders scheduled for late May 2026. The current leadership team...
Sugi Holdings Boosts December Sales on Strong Prescription Growth and Store Expansion
Jan 15, 2026
Sugi Holdings reported that in December 2025, existing-store sales at Sugi Pharmacy rose 0.7% year-on-year, as a 2.5% decline in the Drugstore Business was more than offset by a 9.7% gain in the Prescription Business, underscoring the growing cont...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.